Full Text View
Tabular View
No Study Results Posted
Related Studies
The Effect of Parathyroidectomy on Renal Function, Endothelial Function, and Blood Pressure
This study is currently recruiting participants.
Verified by Universitaire Ziekenhuizen Leuven, March 2009
First Received: March 23, 2007   Last Updated: March 5, 2009   History of Changes
Sponsored by: Universitaire Ziekenhuizen Leuven
Information provided by: Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier: NCT00452049
  Purpose

Secondary hyperparathyroidism (HPT) is a known complication of chronic renal failure. Elevated concentrations of parathyroid hormone (PTH) play a role not only in the pathogenesis of renal bone disease, but also in the development of cardiovascular risk factors such as disturbed lipid metabolism, glucose intolerance, and hypertension. HPT is also known to play an important role in the development of structural abnormalities of both large arteries and the heart (left ventricular hypertrophy, interstitial fibrosis). In the last couple of years there has been increasing evidence from animal studies that the endothelium is a target organ of PTH.

Hypothesis: PTH has clinically relevant effects on renal hemodynamics, renal function and endothelial function.

Aims:

  1. To evaluate the effect of parathyroidectomy (PTX) on renal hemodynamics in stable renal transplant recipients
  2. To evaluate the effect of PTX on endothelial function in stable renal transplant recipients/chronic kidney disease (CKD) stage 5 patients
  3. To evaluate the effect of PTX on blood pressure in stable renal transplant recipients/CKD stage 5 patients

Condition Intervention
Hyperparathyroidism
Hypertension
Procedure: parathyroidectomy

Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Observational Study to Evaluate the Effect of Parathyroidectomy on Renal Function, Endothelial Function and Blood Pressure

Resource links provided by NLM:


Further study details as provided by Universitaire Ziekenhuizen Leuven:

Biospecimen Retention:   Samples Without DNA

Biospecimen Description:

Estimated Enrollment: 20
Study Start Date: April 2005
  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Study Population

Renal transplant recipients

Criteria

Inclusion Criteria:

  1. Stable renal transplant recipients/CKD stage 5D patients.
  2. Age between 18 years and 85 years.
  3. Signed informed consent.
  4. PTX scheduled because of severe hyperparathyroidism (day 0)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00452049

Contacts
Contact: Pieter Evenepoel, MD, PhD 003216344580 pieter.evenepoel@uz.kuleuven.ac.be

Locations
Belgium
University Hopsital Leuven Recruiting
Leuven, Belgium, 3000
Contact: Pieter Evenepoel, MD, PhD     003216344580     pieter.evenepoel@uz.kuleuven.ac.be    
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Investigators
Principal Investigator: Pieter Evenepoel, MD, PhD University Hospital Leuven
  More Information

No publications provided

Responsible Party: University Hospitals leuven ( Prof Vanrenterghem )
Study ID Numbers: ML3052
Study First Received: March 23, 2007
Last Updated: March 5, 2009
ClinicalTrials.gov Identifier: NCT00452049     History of Changes
Health Authority: Belgium: Directorate general for the protection of Public health: Medicines

Keywords provided by Universitaire Ziekenhuizen Leuven:
parathyroidectomy
arterial stiffness
renal function

Study placed in the following topic categories:
Parathyroid Diseases
Hyperparathyroidism
Vascular Diseases
Endocrine System Diseases
Endocrinopathy
Hypertension

Additional relevant MeSH terms:
Parathyroid Diseases
Hyperparathyroidism
Vascular Diseases
Endocrine System Diseases
Cardiovascular Diseases
Hypertension

ClinicalTrials.gov processed this record on September 10, 2009